Mounjaro, DailyMed (2026) FDA approves new medication for chronic weight management, US Food and Drug Administration (2023) Mounjaro, PDR Tirzepatide, StatPearls (2024) Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025), Healthcare (Basel, Switzerland) (2025) Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity, Sleep Medicine (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
The metabolic effects of growth hormone in adipose tissue
His legal complaint accuses Novo Nordisk of designing a dangerous drug (Ozempic) and failing to warn patients about the potential link between Ozempic and sudden blindness
10.3389/FNUT.2022.1022650 Summary Keywords papillary thyroid cancer, DPP-IV, Isglt2, adjuvant therapy, thyroid cancer Citation Buczyska A, Kociuszko M, Krtowski AJ and Popawska-Kita A (2024) Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review